You are here: vision-research.eu » People » Researcher » Navea, Amparo

Amparo Navea

Short CV

1985 MD, PhD, Universidad de Cadiz
1987-91 Residence ophtalmolgy, Hospital La Fe, Valencia
1992-2004 Staff retina section Hospital La Fe
2005- Medical Director Fundación Oftalmógica del Mediterráneo

Documents

CV of Amparo Navea [pdf]

Scientifc Interest

  • Retinal diseases,
  • aged-related macular degeneration,
  • degenerative process like degenerative myopia, diabetic retinopathy.
  • Preventive medicine for retinal diseases

Memberships

  • Sociedad Española Oftalmología
  • Sociedad Española Vitreo Retina
  • Association for Research in Vision and Ophthalmology (ARVO)
  • AAO
Amparo Navea
Amparo Navea

Research Group

Unidad de Retina

Contact

Fundación Oftalmológica del Mediterráneo

Bifurcacion Pio Baroja-Gral Aviles s/n
46015 ValenciaSpain

Phone: +34962328100
Fax: +34962328102

Email:
Navea_amp[at]gva.es

Website:
www.fom.es

Key Publications

  1. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.
    Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A.
    Retina. 2009 Apr;29(4):530-5.
  2. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study
    Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A.
    Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):277-84.
  3. Prospective Clinical Trial Evaluating the Efficacy of Photodynamic Therapy for Symptomatic Circumscribed Choroidal Hemangioma
    A .Boixadera, A; Arumi, JG; Martinez-Castillo, V; Encinas, JL; Elizalde, J; Blanco-Mateos, G; Caminal, J; Capeans, C; Armada, F; Navea, A; Olea, JL
    OPHTHALMOLOGY, 116 (1): 100-105 JAN 2009
  4. One-year follow-up of combined personalized photodynamic therapy and bevacizumab, for exudative age-related macular degeneration
    Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E.
    Retina. 2009 Jan;29(1):13-9.
  5. Clinical magnification and residual refraction after implantation of a double intraocular lens system in patients with macular degeneration.
    Amselem L, Diaz-Llopis M, Felipe A, Artigas JM, Navea A, Garcia-Delpech S.
    J Cataract Refract Surg 2008;34:1571-1577
  6. Transient Bevacizumab (Avastin)-Induced Alterations in Rat Eyes
    Sancho-Tello, M ; Johnsen-Soriano, S; Muriach, M; Bosch-Morell, F; Diaz-Llopis, M; Palacios-Pozo, E; Navea, A; Romero, FJ.
    OPHTHALMIC RESEARCH, 41 (1): 28-35 2009
  7. Early lipoic acid intake protects retina of diabetic mice
    Johnsen-Soriano, S; Garcia-Pous, M; Arnal, E; Sancho-Tello, M; Garcia-Delpech, S; Miranda, M; Bosch-Morell, F; Diaz-Llopis, M; Navea, A; Romero, FJ)
    FREE RADICAL RESEARCH, 42 (7): 613-617 2008
  8. Papillary haemangioma treated with photodynamic therapy.
    A. Navea, F. Pastor-Pascual, A. Lanzagorta, C Desco, E. España.
    RETINAL Cases & Brief Reports. 2(4):328-331, 2008.
  9. Optical análisis to predict outcomes alter implantation of a double intraocular lens magnification device
    A. Felipe, M. Diaz-Llopis, A. Navea, J. Artigas
    J Cataract Referact Surg 2007;33:1781-1789
  10. Identification of 14 Novel Mutations in the Long Isoform of USH2A in Spanish Patients with Usher Syndrome Type II.
    E Aller, T Jaijo, M Beneyto, C Nájera, S Oltra, C Ayuso, M Baiget, M Carballo, G Antiñolo, D Valverde, F Moreno, C Vilela, D Collado, H Pérez-Garrigues, A Navea, JM Millán.
    Journal of Medical Genetics. 43(11):e55, 2006.

Research Groups

People

Missing some information on vision-research.eu?

* mandatory field